Cyclacel Pharmaceuticals, Inc. Announces Data Safety Monitoring Board Recommendation To Continue The SEAMLESS Phase 3 Trial Of Sapacitabine In AML

Published: Nov 25, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY HEIGHTS, N.J., Nov. 25, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 SEAMLESS study in acute myeloid leukemia (AML) has completed its third planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 212 randomized patients and noted that no safety or efficacy concerns were identified. The DSMB will conduct additional periodic reviews of each 100 patients and will also perform a futility assessment once half the required events have been observed.

Help employers find you! Check out all the jobs and post your resume.

Back to news